Disease Overview：Acute Myeloid Leukemia（AML）
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. It disrupts normal hematopoiesis, leading to cytopenias—such as anemia, neutropenia, and thrombocytopenia—and carries significant risk of life-threatening infections, bleeding, and organ infiltration. AML incidence rises with age, with median diagnosis occurring in the sixth decade; however, it can affect younger adults and children. Risk stratification relies on cytogenetic profiling (e.g., t(8;21), inv(16), FLT3-ITD, NPM1 mutations) and molecular testing to guide prognosis and therapeutic decisions. Standard induction therapy typically involves cytarabine plus an anthracycline (e.g., daunorubicin or idarubicin), followed by consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for eligible high-risk or relapsed/refractory cases. Emerging targeted agents—including FLT3 inhibitors (gilteritinib), IDH1/2 inhibitors (ivosidenib, enasidenib), and venetoclax-based regimens—have improved outcomes, particularly in older or unfit patients.
China offers distinct advantages for AML management: its top-tier hematology centers—many affiliated with Peking University People’s Hospital, Shanghai Ruijin Hospital, and Sun Yat-sen University Cancer Center—combine deep expertise in complex leukemia biology with extensive experience in minimal residual disease (MRD) monitoring, haploidentical HSCT, and novel immunotherapies. Advanced infrastructure includes next-generation sequencing platforms, flow cytometry with ≥10-color panels, and PET-CT–guided response assessment. Five-year overall survival rates for standard-risk AML exceed 60% in leading institutions, with over 1,200 allo-HSCT procedures performed annually at select centers. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical rigor—making intensive regimens and transplant more accessible. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital accreditation, coordinating multidisciplinary consultations, providing itemized, transparent pricing in advance, arranging visa support and local logistics, and offering bilingual case management throughout diagnosis, treatment, and follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Acute Myeloid Leukemia (AML)
Non-Surgical / Medical Therapy
*Indications:* Newly diagnosed AML, relapsed/refractory disease, unfit for intensive chemotherapy or transplant.
- •Induction Chemotherapy (7+3 regimen)
- *Cost (per cycle):* $2,800–$4,200 - Cytarabine (100 mg/m² × 7 days): $1,100 - Daunorubicin (60 mg/m² × 3 days): $950 - Supportive care (G-CSF, antibiotics, transfusions): $750
- •Targeted Therapy (FLT3-mutated AML)
- *Cost (30-day supply):* $3,600–$5,100 - Midostaurin: $3,600 - Gilteritinib (relapsed): $5,100 - NGS panel (blood/bone marrow): $420
- •Hypomethylating Agents (Unfit patients)
- *Cost (per 28-day cycle):* $1,900–$2,700 - Azacitidine (75 mg/m² × 7 days): $1,900 - Decitabine (20 mg/m² × 5 days): $2,700 - Bone marrow biopsy + morphology: $280
Procedural / Interventional Options
*Indications:* Consolidation therapy, curative intent in eligible patients.
- •Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- *Preoperative Workup (mandatory):* $1,350 - PET-CT + pulmonary function test: $620 - Cardiac echo + Holter: $410 - Donor HLA typing + chimerism assay: $320 - *Transplant Procedure (including conditioning, infusion, 30-day inpatient care):* $38,000–$52,000 - Myeloablative (e.g., Bu/Cy): $48,500 - Reduced-intensity (e.g., Flu/Mel): $38,000 - GVHD prophylaxis (tacrolimus + methotrexate): $1,200
- •Autologous HSCT (rare, investigational in AML)
- *Cost:* $29,000–$35,000 (includes mobilization, apheresis, cryopreservation, reinfusion)
Special/Complex Condition Management
- •AML with CNS involvement: Intrathecal cytarabine + high-dose IV cytarabine → $6,800/cycle
- •Relapsed/refractory AML with TP53 mutation: Venetoclax + azacitidine → $7,200/month
- •Post-transplant relapse: Donor lymphocyte infusion (DLI) → $4,500/dose
Quick Selection Guide
- •<60 years, fit, no comorbidities: Induction (7+3) → allo-HSCT in CR1 ($41,000–$56,000 total)
- •60–75 years, moderate comorbidities: Venetoclax + azacitidine ($7,200–$14,400 first 2 months)
- •≥75 years or severe organ dysfunction: Hypomethylating agent monotherapy ($1,900–$2,700/month)
- •FLT3-mutated, newly diagnosed: Midostaurin + 7+3 ($6,400–$8,400 induction phase)
- •Budget-constrained (<$10,000): Standard induction + supportive care only ($2,800–$4,200) — survival benefit limited without consolidation.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Acute Myeloid Leukemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Acute Myeloid Leukemia treatment with China top medical destinations:
